"For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during labor and two more after giving birth, an international clinical trial has found.
"The ongoing PROMISE (Promoting Maternal-Infant Survival Everywhere) study also has found that one triple-drug regimen for preventing mother-to-child transmission may be safer than another for women and their babies."
For more information, read the NIH press release.
"The guidance provides the FDA's current thinking for development of vaginal microbicides for the prevention of human immunodeficiency virus (HIV) infection. The final guidance supersedes the 2012 draft guidance and incorporates the FDA’s responses to public comments submitted to the Agency.
"The guidance addresses issues related to nonclinical development, early phases of clinical development, phase 3 trial considerations, and safety considerations in vaginal microbicide development, including safety considerations in adolescent and pregnant populations."
For more information, read the FDA press release or view the guidance.
The Centers for Disease Control and Prevention (CDC) recently released the 2012 HIV Surveillance Report. The report presents data from the National HIV Surveillance System on diagnoses of HIV infection in the United States and 6 dependent areas. The data in this report are used by federal agencies, health departments, and other organizations to help focus prevention efforts, allocate resources, and monitor trends in HIV infection.
The theme of World AIDS Day 2014 is "Focus, Partner, Achieve: An AIDS-free Generation." The theme represents both the progress and the ongoing challenges in the global fight against HIV/AIDS. Successes include the wider availability of life-saving antiretroviral drugs, advances in HIV vaccine research, and declines in mother-to-child transmission of HIV. To meet the challenge of an AIDS-free generation, partners worldwide will continue to focus on eliminating new HIV infections and AIDS-related deaths.

Visit our World AIDS Day webpage [en español] to learn more about this annual observance. The page includes links to HIV-related information from AIDSinfo and other sources.
The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents announces the release of the updated Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. As described in What's New in the Guidelines, this interim revision of the guidelines features a revised section on Hepatitis C (HCV)/HIV Coinfection that emphasizes considerations for use of antiretroviral (ARV) drugs in patients who also receive treatment for HCV infection. The section includes a new table (Table 12) that provides clinicians with guidance on the concomitant use of HCV drugs and ARV drugs with a focus on potential pharmacokinetic drug interactions.
To view or download the guidelines, go to the Adult and Adolescent ARV Guidelines section of AIDSinfo. Separate PDF files that include only the guideline tables or boxed recommendations can also be downloaded from the page.
Forward Comments on the Revised Guidelines to AIDSinfo
Feedback on the revised Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents is welcome. Please e-mail your comments with the subject line "Comments on the Adult and Adolescent ARV Guidelines" to by November 30, 2014.
AIDSinfo invites you to view our patient fact sheets on three medications recently approved by the FDA. The three medications are all indicated for use in the treatment of HIV infection in adults. The patient fact sheets include information on dosage forms and strengths, possible side effects, and instructions on how to take and store the medications.
  • Fact sheet on cobicistat (brand name: Tybost)

    Cobicistat is a pharmacokinetic enhancer indicated for use with atazanavir (brand name: Reyataz) or darunavir (brand name: Prezista) to increase the amount of those medicines in the blood; it must be used in combination with other HIV medicines as well. 
  • Fact sheet on elvitegravir (brand name: Vitekta)

    Elvitegravir is an integrase inhibitor approved to treat HIV infection in adults who are already taking or have previously taken HIV medicines. Elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir (brand name: Norvir) and another HIV medicine.
Visit the Drugs section of the AIDSinfo website to view the fact sheets and FDA labels for the three medications.


  • Categories:

    • Locations: